COX-2 is progressively overexpressed during the stepwise sequence from adenoma to carcinoma and, in randomized, placebo-controlled trials, has shown that selective COX-2 inhibitors prevent recurrence of adenoma among patients with a history of adenoma or familial polyposis [18, 19]. Here, PTGS2 is linked to adenoma.